Sugi Predict

Sugi Predict / Compounds / SCHEMBL722256

SCHEMBL722256

SCHEMBL722256

Cn1cccc1C(=O)N1CCc2cc(C(=O)NO)ccc2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 19/20 1.00
▸ HDAC8 Q9BY41 6/20 1.00
▸ HDAC3 O15379 2/20 1.00
▸ HDAC1 Q13547 2/20 1.00
▸ KMT2A Q03164 1/20 0.67
▸ HDAC7 Q8WUI4 1/20 0.62
▸ HDAC2 Q92769 1/20 0.62
▸ HDAC10 Q969S8 1/20 0.62
▸ HDAC11 Q96DB2 1/20 0.62
▸ HDAC5 Q9UQL6 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1264321 0.94 HDAC6 (1.00) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL1264164 0.93 HDAC6 (1.00) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL1263733 0.90 HDAC6 (1.00) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL720436 0.87 HDAC6 (0.78) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL10224190 0.84 HDAC6 (0.72) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL10224065 0.84 HDAC6 (0.72) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL17960512 0.83 HDAC6 (0.71) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL1174737 0.80 HDAC6 (1.00) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL1173968 0.80 HDAC6 (1.00) HDAC6HDAC8HDAC3HDAC1KMT2A
SCHEMBL1080738 0.79 HDAC6 (0.67) HDAC6HDAC8HDAC3HDAC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116510024-A Composition, preparation method and application thereof 上海复东生物医药有限责任公司 2023-08-01 — — CN claimed
CN-114908049-A Use of HDAC6 inhibitors to selectively induce T cell expansion 江苏集萃医学免疫技术研究所有限公司 2022-08-16 — — CN claimed
WO-2016120432-A1 COMPOUNDS AND METHODS FOR ANTICOAGULATION THERAPY FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-08-04 — — WO claimed
CN-115192714-B Use of HDAC6 inhibitors in the manufacture of a medicament for the treatment of DNMT3A gene-deficient cancers 沈阳药科大学 2024-09-17 — — CN disclosed
CN-116510024-A Composition, preparation method and application thereof 上海复东生物医药有限责任公司 2023-08-01 — — CN disclosed
US-20230190717-A1 P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF CITY OF HOPE 2023-06-22 — — US disclosed
US-20220401474-A1 HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF MEDSTAR HEALTH 2022-12-22 — — US disclosed
CN-114908049-A Use of HDAC6 inhibitors to selectively induce T cell expansion 江苏集萃医学免疫技术研究所有限公司 2022-08-16 — — CN disclosed
US-11225665-B2 P38 map kinase inhibitors CITY OF HOPE (US) 2022-01-18 — — US disclosed
US-20200399643-A1 P38 MAP KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-12-24 — — US disclosed
EP-2445340-B1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARM INC (US) 2016-05-18 — — EP disclosed
US-20140142108-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARM INC (US) 2014-05-22 — — US disclosed
US-8471026-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-25 — — US disclosed
EP-2445340-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2012-05-02 — — EP disclosed
US-20120053201-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-03-01 — — US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 — — US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 — — US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 — — US disclosed
WO-2010151318-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 — — WO disclosed
WO-2010151318-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053201-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC8 16/4885HDAC3 5/4885
US-20220401474-A1 HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF HDAC6, HDAC1, HDAC3 HDAC6 1/4885HDAC8 6/4885HDAC3 3/4885
US-20110039827-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 HDAC6 1/4885HDAC8 11/4885HDAC3 4/4885
US-20230190717-A1 P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF CDC42BPG, MAPK1, MAPK7 HDAC6 564/4885HDAC8 497/4885HDAC3 931/4885
US-20140142108-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC8 16/4885HDAC3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.